Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDF Dose Adjustment vs Switching to TAF in Chronic Hepatitis B
NCT04391608Phase 4Unknown
- Sponsor
- Mahidol University
- Start
- Nov 2019
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tenofovir alafenamide in hepatitis B (HBV), sponsored by Mahidol University. Status: unknown.
02
Drugs
tenofovir alafenamide
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04391608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04391608.